Replicate Bioscience takes aim at mono-causing virus after promising results with mRNA rabies shot

14 Feb 2024
endpts.com
VaccinemRNAClinical StudyImmunotherapy
Replicate Bioscience, a San Diego startup developing a second-generation mRNA vaccine technology that could spur stronger immunity with smaller doses, said its experimental rabies shots performed better than expected in an 84-person clinical trial.
In an exclusive interview with Endpoints News, CEO Nathaniel Wang said his company plans to raise a Series B round based on the rabies data. But without a pharma or government partner, Replicate is unlikely to advance the rabies shot into a larger study, he added.
Replicate Bioscience takes aim at mono-causing virus after promising results with mRNA rabies shot
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.